Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoret...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, D., Franchini, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927574/
https://www.ncbi.nlm.nih.gov/pubmed/33675992
http://dx.doi.org/10.1016/j.tracli.2021.02.005
Descripción
Sumario:Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs.

Ejemplares similares